The Slack Guy's Path To The Gemcitabine Triumph

The cumulative percentage of lymphomas for risk factors was computed using the Kaplan�CMeier survival method. Risk factors were analyzed by univariate analysis using a Cox proportional hazard model; variables with p 12 months), EBV positive and negative PTLD, polymorphic and monomorphic PTLD, graft and cerebral PTLD��were studied using univariate analysis. Statistical analyses were performed using SAS software version 9.2. Cumulative incidence was 1% PY 5 years and 2.1% PY 10 years posttransplant (Figure 1A). Incidence was slightly higher in the 1st year, leveled off in the 2nd year and remained http://www.selleckchem.com/products/Gemcitabine-Hydrochloride(Gemzar).html stable until the 7th year, and then increased in the 8th�C10th year (Figure 1B). Analyzing PTLD incidence according to the period of transplantation (Figure 1C) revealed a decrease in lymphoma incidence during the first 3 years posttransplant in the more recent period (2002�C2005 vs. 1998�C2001, http://www.selleck.cn/products/azd9291.html p http://www.selleckchem.com/products/birinapant-tl32711.html in the 181 recipients at the time of PTLD diagnosis. Treatment and outcome of patients with PTLD are detailed in Table 3. Thirty-five patients lost their graft (19%) leading to a graft survival of 88% at 1 year and 60% at 5 years (vs. respectively 91% and 80% in patients without lymphoma, p 46 years), deceased donor, simultaneous kidney-pancreas transplantation, year of transplant (before 2001), duration of dialysis (